Sanofi : Un risque/reward qui reste attractif autour de son pipeline
>Tolebrutinib rassure le marché - Les résultats topline positifs de l’essai HERCULES (sclérose en plaques secondairement progressive non active) a permis de rassurer le marché sur les ambitions de tolebrutinib. L’échec des essais GEMINI 1 & 2 conduira Sanofi à préciser dans quelques mois sa guidance de pic de ventes pour le médicament. Initialement anticipé entre 2 et 5 Md€ toutes indications confondues, celle-ci devrait s’ajuster entre 1.5 et 3 Md€ dépendant par la ...Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.